Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Craig Primack stated in part: “In my experience of treating thousands of people, lasting results come from focusing on the individual, not just the condition. This simple belief has shaped the way ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

liraglutide. Hims & Hers previously offered only cheaper versions of Novo's weight-loss drug Wegovy. "The increased level of product availability broadens HIMS' weight loss offerings, which is a ...

Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli ...

In a statement posted to the newsroom of Hims & Hers (HIMS), Craig Primack ... that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform.